This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Society affairs & governance

EAS is pleased to endorse International Symposium HDL-Beyond atherosclerosis

Friday 19 October 2018  
Share |

Meeting: HDL-Beyond Atherosclerosis in Milan, Italy.
Date: February 01, 2019
Venue: University of Milan - La Statale; Department of Pharmacological and Biomolecular Science
Contact: Mr Massimiliano Ruscica
               
Massimiliano.ruscica@unimi.it
               Tel. +393383661987

The clinical utility of high density lipoproteins (HDL) in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) has been scrutinized in recent years by the failures of randomized controlled intervention trials as well as the lack of association between HDL-Cholesterol modifying variants and ASCVD outcome. 

HDL exert multiple functions that contribute to host defense from biological or chemical harm and mediate repair of tissue damage. These protective functions make HDL interesting therapeutic targets beyond the management of ASCVD.
In fact recent epidemiological, clinical, genetic and experimental research indicate the involvement of HDL in many pathologies including diabetes, nephropathies, infections, chronic inflammatory diseases, cancers, and age-related macular degeneration.

Unravelling the molecular basis of these protective effects and associations may improve the management of these and other diseases. In addition, artificial HDL may be used for the delivery of tracers and drugs for imaging and targeted treatment.
The one-day meeting aims to summarize the recent progress in this novel direction of HDL research.

For further information about this meeting see: HDL-Beyond Atherosclerosis Programme


Membership Software Powered by YourMembership  ::  Legal